FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912385217> ?p ?o ?g. }

• W2912385217 endingPage "5719" @default.
• W2912385217 startingPage "5700" @default.
• W2912385217 abstract "The tumor suppressor bridging integrator 1 (BIN1) is a corepressor of the transcription factor E2F1 and inhibits cell-cycle progression. BIN1 also curbs cellular poly(ADP-ribosyl)ation (PARylation) and increases sensitivity of cancer cells to DNA-damaging therapeutic agents such as cisplatin. However, how BIN1 deficiency, a hallmark of advanced cancer cells, increases cisplatin resistance remains elusive. Here, we report that BIN1 inactivates ataxia telangiectasia–mutated (ATM) serine/threonine kinase, particularly when BIN1 binds E2F1. BIN1 + 12A (a cancer-associated BIN1 splicing variant) also inhibited cellular PARylation, but only BIN1 increased cisplatin sensitivity. BIN1 prevented E2F1 from transcriptionally activating the human ATM promoter, whereas BIN1 + 12A did not physically interact with E2F1. Conversely, BIN1 loss significantly increased E2F1-dependent formation of MRE11A/RAD50/NBS1 DNA end-binding protein complex and efficiently promoted ATM autophosphorylation. Even in the absence of dsDNA breaks (DSBs), BIN1 loss promoted ATM-dependent phosphorylation of histone H2A family member X (forming γH2AX, a DSB biomarker) and mediator of DNA damage checkpoint 1 (MDC1, a γH2AX-binding adaptor protein for DSB repair). Of note, even in the presence of transcriptionally active (i.e. proapoptotic) TP53 tumor suppressor, BIN1 loss generally increased cisplatin resistance, which was conversely alleviated by ATM inactivation or E2F1 reduction. However, E2F2 or E2F3 depletion did not recapitulate the cisplatin sensitivity elicited by E2F1 elimination. Our study unveils an E2F1-specific signaling circuit that constitutively activates ATM and provokes cisplatin resistance in BIN1-deficient cancer cells and further reveals that γH2AX emergence may not always reflect DSBs if BIN1 is absent. The tumor suppressor bridging integrator 1 (BIN1) is a corepressor of the transcription factor E2F1 and inhibits cell-cycle progression. BIN1 also curbs cellular poly(ADP-ribosyl)ation (PARylation) and increases sensitivity of cancer cells to DNA-damaging therapeutic agents such as cisplatin. However, how BIN1 deficiency, a hallmark of advanced cancer cells, increases cisplatin resistance remains elusive. Here, we report that BIN1 inactivates ataxia telangiectasia–mutated (ATM) serine/threonine kinase, particularly when BIN1 binds E2F1. BIN1 + 12A (a cancer-associated BIN1 splicing variant) also inhibited cellular PARylation, but only BIN1 increased cisplatin sensitivity. BIN1 prevented E2F1 from transcriptionally activating the human ATM promoter, whereas BIN1 + 12A did not physically interact with E2F1. Conversely, BIN1 loss significantly increased E2F1-dependent formation of MRE11A/RAD50/NBS1 DNA end-binding protein complex and efficiently promoted ATM autophosphorylation. Even in the absence of dsDNA breaks (DSBs), BIN1 loss promoted ATM-dependent phosphorylation of histone H2A family member X (forming γH2AX, a DSB biomarker) and mediator of DNA damage checkpoint 1 (MDC1, a γH2AX-binding adaptor protein for DSB repair). Of note, even in the presence of transcriptionally active (i.e. proapoptotic) TP53 tumor suppressor, BIN1 loss generally increased cisplatin resistance, which was conversely alleviated by ATM inactivation or E2F1 reduction. However, E2F2 or E2F3 depletion did not recapitulate the cisplatin sensitivity elicited by E2F1 elimination. Our study unveils an E2F1-specific signaling circuit that constitutively activates ATM and provokes cisplatin resistance in BIN1-deficient cancer cells and further reveals that γH2AX emergence may not always reflect DSBs if BIN1 is absent." @default.
• W2912385217 created "2019-02-21" @default.
• W2912385217 creator A5008902588 @default.
• W2912385217 creator A5019445232 @default.
• W2912385217 creator A5023214532 @default.
• W2912385217 creator A5030717880 @default.
• W2912385217 creator A5060099887 @default.
• W2912385217 creator A5072738885 @default.
• W2912385217 creator A5084336728 @default.
• W2912385217 creator A5091613913 @default.
• W2912385217 date "2019-04-01" @default.
• W2912385217 modified "2023-10-09" @default.
• W2912385217 title "Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin" @default.
• W2912385217 cites W1480834102 @default.
• W2912385217 cites W1507706498 @default.
• W2912385217 cites W1538419182 @default.
• W2912385217 cites W1553367038 @default.
• W2912385217 cites W1966419893 @default.
• W2912385217 cites W1970841420 @default.
• W2912385217 cites W1971419576 @default.
• W2912385217 cites W1972402664 @default.
• W2912385217 cites W1980411311 @default.
• W2912385217 cites W1984881284 @default.
• W2912385217 cites W1987322786 @default.
• W2912385217 cites W1989147967 @default.
• W2912385217 cites W1990280364 @default.
• W2912385217 cites W1996243898 @default.
• W2912385217 cites W1998070942 @default.
• W2912385217 cites W1998129814 @default.
• W2912385217 cites W2005953598 @default.
• W2912385217 cites W2012108057 @default.
• W2912385217 cites W2014300705 @default.
• W2912385217 cites W2015257039 @default.
• W2912385217 cites W2015925058 @default.
• W2912385217 cites W2027630134 @default.
• W2912385217 cites W2029383449 @default.
• W2912385217 cites W2034831440 @default.
• W2912385217 cites W2036223578 @default.
• W2912385217 cites W2039143648 @default.
• W2912385217 cites W2047660841 @default.
• W2912385217 cites W2051388309 @default.
• W2912385217 cites W2057949133 @default.
• W2912385217 cites W2060372099 @default.
• W2912385217 cites W2061019285 @default.
• W2912385217 cites W2061197983 @default.
• W2912385217 cites W2067328670 @default.
• W2912385217 cites W2071457560 @default.
• W2912385217 cites W2077631241 @default.
• W2912385217 cites W2089574530 @default.
• W2912385217 cites W2096719176 @default.
• W2912385217 cites W2099607826 @default.
• W2912385217 cites W2106493014 @default.
• W2912385217 cites W2110744505 @default.
• W2912385217 cites W2135166153 @default.
• W2912385217 cites W2135789424 @default.
• W2912385217 cites W2137106310 @default.
• W2912385217 cites W2141037581 @default.
• W2912385217 cites W2143671238 @default.
• W2912385217 cites W2145932100 @default.
• W2912385217 cites W2146693531 @default.
• W2912385217 cites W2150748567 @default.
• W2912385217 cites W2155318349 @default.
• W2912385217 cites W2159515687 @default.
• W2912385217 cites W2161340431 @default.
• W2912385217 cites W2161681893 @default.
• W2912385217 cites W2164660679 @default.
• W2912385217 cites W2567230103 @default.
• W2912385217 cites W2604619953 @default.
• W2912385217 cites W2624467319 @default.
• W2912385217 cites W2780646907 @default.
• W2912385217 cites W4212962560 @default.
• W2912385217 doi "https://doi.org/10.1074/jbc.ra118.005699" @default.
• W2912385217 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6462522" @default.
• W2912385217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30733337" @default.
• W2912385217 hasPublicationYear "2019" @default.
• W2912385217 type Work @default.
• W2912385217 sameAs 2912385217 @default.
• W2912385217 citedByCount "17" @default.
• W2912385217 countsByYear W29123852172020 @default.
• W2912385217 countsByYear W29123852172021 @default.
• W2912385217 countsByYear W29123852172022 @default.
• W2912385217 countsByYear W29123852172023 @default.
• W2912385217 crossrefType "journal-article" @default.
• W2912385217 hasAuthorship W2912385217A5008902588 @default.
• W2912385217 hasAuthorship W2912385217A5019445232 @default.
• W2912385217 hasAuthorship W2912385217A5023214532 @default.
• W2912385217 hasAuthorship W2912385217A5030717880 @default.
• W2912385217 hasAuthorship W2912385217A5060099887 @default.
• W2912385217 hasAuthorship W2912385217A5072738885 @default.
• W2912385217 hasAuthorship W2912385217A5084336728 @default.
• W2912385217 hasAuthorship W2912385217A5091613913 @default.
• W2912385217 hasBestOaLocation W29123852171 @default.
• W2912385217 hasConcept C105696609 @default.
• W2912385217 hasConcept C121608353 @default.
• W2912385217 hasConcept C134935766 @default.
• W2912385217 hasConcept C143425029 @default.
• W2912385217 hasConcept C153911025 @default.
• W2912385217 hasConcept C183022183 @default.

• next